SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant [X]

Filed by a Party other than the Registrant [   ]

Check the appropriate box:

[   ]	Preliminary Proxy Statement
[   ]	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
[   ]	Definitive Proxy Statement
[X]	Definitive Additional Materials
[   ]	Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12

SciClone Pharmaceuticals, Inc.

(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box):

[X]	No fee required.
[   ]	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
		(1)	Title of each class of securities to which transaction applies:
		(2)	Aggregate number of securities to which transaction applies:
		(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
		(4)	Proposed maximum aggregate value of transaction:
		(5)	Total fee paid:
[   ]		Fee paid previously with preliminary materials.
[   ]		Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
		(1)	Amount Previously Paid:
		(2)	Form, Schedule or Registration Statement No.:
		(3)	Filing Party:
		(4)	Date Filed:

IMPORTANT REMINDER

May 2, 2002

Dear Shareholder:

     Your proxy has not yet been received for the Annual Meeting of Shareholders of SciClone Pharmaceuticals, Inc. (SCLN) to be held on Thursday, May 30, 2002. No matter how many or how few shares you own, your vote is important.

     Among other important proposals, you are being asked to consider and vote on a proposal to approve and ratify the reincorporation of SciClone Pharmaceuticals from California to Delaware and other related proposals. This change is intended to protect shareholder value and must be voted personally by shareholders.

     A vote FOR the proposals is recommended by The Board of Directors of SciClone Pharmaceuticals. The proposals and the Board recommendation are explained in greater detail in the Proxy Statement previously sent to you. A copy can also be found at www.sciclone.com/investorrelations.

     Please take the time today to sign, date and return the enclosed duplicate proxy in the postage paid envelope as soon as possible or follow the instructions on the enclosed proxy to vote via the internet or telephone.

Sincerely,

/s/  Donald R. Sellers

Donald R. Sellers
President and Chief Executive Officer

GRAPHIC 3 f80394xf80394l1.gif GRAPHIC begin 644 f80394xf80394l1.gif M1TE&.#EAG@`U`-4``#-FF0"9FO'Q\>/CX___S,S,S)F9S.KJZN_6QOCX^-?7 MV```,O^9`-W=W0"`@&9FF<#`P#,S9J"@I,QF`,O+R\PS`,S,,P!FS`!F9J;* M\,SL_^?GUO_,,___`)G,,V:9S+*RLF:99IF99C.9F0"99C.99IF9F`#4```;_ MP)]P2"P:C\BD$PNF\_HM'K-;KO?\+A\ M3J]K!Q!=9A!74"`0=FP//0N&ACTX.PEH"CLXA8@]`()H!@L^/3H'/P,ZD#T] MC&,##YD]/CLZ.@8^/@^59CNH/@)&.YD*8A2G/3N<1"`]!K%D`ZB^2(0Z8`.9 MF91'!CVZQ6(XKCT-2`T]$E^$V11)LWS68:ZY2:E=`L^N2SK1YU\"M#[S1A([ M7,?9&/3D@(X%N`%&V&(`'FA?%2;%G$*B%FA=E0S.'5L(,)WJ#@[1>;Q8`I$@OR.A`=@20F$E;*\_/C8< M/\75AR0-,N45DDE?IHZWO@_!Y6/^#Z,[9```0-E-Y\"!E.UD00C814?`$AD4 MQ9X0.A3BWP\*S"9$!*YDI/]>.C-!46$/=!F!4")%$**?$%PE4P0,%V8S4RT_ M[%#`#B`0D%T("":X$P<[6!7==DNPELU+%(928A(#X<=B0Z51H9YB14Q9!']% M1."/443X0.5_/CCY`WL'1.#(!X[I%(*/E4$F'0\WB,!!$TBYXJ0]*#)1`"HK M?MCA%`FX$J41"M!BA"F[F:90A9GPUD,1(ZZH#1$2%.!##AR(L`-5/(V0'0\B MB.##H$H<<(\H0B`Z81*(HO=#.-GP]L1`2@DQRW!&8-.#8A*\=*M"0SQ*!*(? M#-"``B8L<,2E5@'):0">9L?!"#EXV<2'/=C2'5.N3/AK)DL^`4%L2.BJX9,] M:##_!%Y#Z!I-?$6D(Q:'DRSK$TXC8&<#M3L%&1T'0)EC0*U"@"!3;ZB0RJ2= M13CC71,0].F*02:F(ZL]GFU(,7V9\$.!F&`"*P2[1MQT`4XY%-A33F[ND!*- M/^``,A'C"BH$!`Q_16Z\'#41@9.!_EEQQONADD^V1&SIR8J\U-ONN;;>Y-,. MGS[64\LO#Q%F$CID\]V>1+.:B:LWGPK"$@HLH!_&,[>;)Q&Z2L2+$6"GXM^M M%R)AZ;T7-!B=!291;0%0^KUMA'JH8TK%MTH$1\A7>41/=Q;DIN.]502!P"DU(-:[DQJ_X0PF6Q<(Y]&^"!1 MDTEPE4X```J+@0HWP`D".X8PC3P(#,.N,#W?',)]H30?=2@H%$$8H5 M'Y!`7*!F0PIDH``AFL)>#"`!)1K&AU/0@`Z(]P2R5<$B&!#!X+IG$?4MY8Q& M:,4,9$!##%BD8T-(&P\O-435'?_HCGAT``E(4((^AB`$*(B!!P9)2`L8T@(G MB$X'%MD!QS2RD56+I"2CPP`&\*"2F,PD)FTP@11,@`&?].0$1DE*4E;@E*A, M9058\!4_10!]&()?.NIHQSSF<8][[&,)`(D"%!!RD(8\@3!/\,A%.G*2R/R4 M)37)3&9^LI2BG,`*2#E-5:JR!15H`2NQD("^]*4`&0AG.#6@``V8\YSF;(`Z MUZE.!0S@G?#<@#SG.4\"U),`^,RG/O?)SW[ZLY\("*A`!TK0@AKTH`-%HT(7 MRE"1X($".F!/`OBR#1U0P(?Y(\(?=""!)>UE-ELL0C=M&)?,%0"B)?)$2%P!+%+43@`?:8S0ZBM*?>A0Y7^*"4L'!Q MN-"Y(Z+Z0 M'T@`9/)8"8U":*M:U&:!$!`+$0H%.5,5ITMT*8"ZND0V`,P#(5@4@@%PL+PA M:$!9\2+&9KQ0@`6PA52^L*@/VMI2*HII3P)(#A$*P!8=.&)%I>@:$2)P4\LM M=CY\M541"F6$",QG!P1CQ2.(P%3&638,.(OH:(6%$-X`0*;3&RH`%$:)C]RH M3S(UHCW>PEM8'$`BNQU3Z'I+!&JTJ[7I<<3T%'$$[GJ!O)#"F\\Q>&N.Q<7L M/3TXFQ`\\0.#O:JQBU&+#]3R@PA$8P`2>>7-UO6U`"(QU.A!^#V>ZG8`2QQ\0!784-W`!B+M6I$HP_TH*T52HYA1R:!XXK$+V?H ...:10@!P4J-_3*30@"`#L_ ` end -----END PRIVACY-ENHANCED MESSAGE-----